CTLA4 and melanoma: As we have observed previously for combination blockade of CTLA-4 and PD-1, we find that co-administration with an autologous tumor vaccine expressing Flt3-ligand allows these antibodies to co-operate in rejecting more than 50% of pre-implanted B16-BL6 melanomas [20].